Open-Label Treatment Trial of Lithium to Target the Underlying Defect in Fragile X Syndrome

Abstract

Results from this study are consistent with results in mouse and fly models of FXS, and suggest that lithium is well-tolerated and provides functional benefits in FXS, possibly by modifying the underlying neural defect. A placebo-controlled trial of lithium in FXS is warranted.